Ligand Targretin Gel NDA Supported By Capsule Data In Lieu Of 2nd Ph. III Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA accepted efficacy data on the capsule formulation of Ligand’s Targretin (bexarotene) as a replacement for a confirmatory Phase III study of Targretin gel 1%, according to FDA review documents.